<DOC>
	<DOCNO>NCT00283985</DOCNO>
	<brief_summary>Nasal/nasal type NK-T-cell lymphoma rare severe type non-Hodgkin 's lymphoma ( NHL ) frequent Asia western country . When localise , radiotherapy seem best treatment . When radiotherapy use dissemination relapse , chemotherapy protocol use type NHL give poor result survival poor . Recently paper China Japan report efficacy drug : l-asparaginase , usually use treat acute lymphoblastic leukemia . In vitro selective apoptosis NK-cell tumours l-asparaginase show tumour cell line sample . The investigator propose phase II protocol patient refractory relapse nasal/nasal type NK-T-cell lymphoma use regimen combine l-asparaginase , methotrexate dexamethasone . Biological study conduct try find factor could predict response chemotherapy . Since january 2009 , study concern patient nasal/nasal type NK-T-cell lymphoma receive asparaginase .</brief_summary>
	<brief_title>Association L-asparaginase-Methotrexate-Dexamethasone Nasal Nasal-type Natural Killer ( NK ) -T-cell Lymphoma</brief_title>
	<detailed_description>Primary Objective : - Determine overall complete response rate Secondary Objectives : - To evaluate survival without progression - To evaluate total survival . - To evaluate tolerance side effect treatment . - To evaluate duration mode hospitalization patient treat therapeutic association . - To constitute bank biological sample - serum , tumoral , ADN , ARN allow prognostic study imply virus EBV , p53 , CD94 , C-kit asparagine synthetase gene order well understand mechanism cancerogenesis variety cytotoxic LNH identify predictive factor response asparaginase . Sampling : For patient include protocol , follow sample carried diagnosis : - Biopsy , - Medullary biopsy - Medullary aspiration - blood : 3 tube 7 ml EDTA 3 tub 7 ml heparin Treatment : All patient include receive three cure separate 3 week ( J1 , J22 , J43 ) : - J1 : Methotrexate 3 gr/m2 - J2 , J4 , J6 J8 : KidrolaseÂ® 6000 u/m2 - J1 J4 : Dexamethasone 40 mg ( 20 mg age &gt; 70 year )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients relapsing/refractory TNK/NK lymphoma : Ages 18 year Patients must diagnosis NKcell ( TNK ) nonHodgkin 's lymphoma , nasal nasaltype . Stage I , II , III , IV disease Creatinine le 3 x upper limit normal ( ULN ) Able give inform consent No prior treatment asparaginase Patients TNK/NK lymphoma ( de novo patient ) : Ages 18 year Patients must diagnosis NKcell ( TNK ) nonHodgkin 's lymphoma , nasal nasaltype . Stage I , II , III , IV disease Creatinine le 3 x upper limit normal ( ULN ) Able give inform consent prior chemotherapy radiotherapy Patients pregnant nurse Any factor might limit patient 's ability provide inform consent Liver insufficiency Evolutive thrombosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>NK/T-cell lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>L-asparaginase</keyword>
	<keyword>Nasal NK-cell lymphoma</keyword>
	<keyword>Nasal-type NK-cell Lymphoma</keyword>
</DOC>